Antiviral Drugs (Synthetic Small Molecule Inhibitors and Nature Drugs) Against EV71 in Enteroviruses: Advances and Perspectives

Liu, Tao; Yuan, Xianglin; Ji, Likai; Shen, Yin; Zhang, Wen; Xue, Mengzhu

doi:10.1016/j.ccmp.2023.100099

Cited by 3 publications

(2 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the development of safe and effective antiviral drugs should be pursued – antivirals are an active area of research, especially against EV-A71, and are reviewed elsewhere [ 48 – 57 ]. Although five EV inhibitors targeting the EV capsid surface have been evaluated for safety and efficacy in clinical trials, a majority of the inhibitors were found to cause unwanted side effects and failed to meet their clinical endpoints [ 58 ].…”

Section: Enterovirusesmentioning

confidence: 99%

Enteroviruses: epidemic potential, challenges and opportunities with vaccines

Jartti,

Flodström-Tullberg,

Hankaniemi

2024

J Biomed Sci

View full text Add to dashboard Cite

Enteroviruses (EVs) are the most prevalent viruses in humans. EVs can cause a range of acute symptoms, from mild common colds to severe systemic infections such as meningitis, myocarditis, and flaccid paralysis. They can also lead to chronic diseases such as cardiomyopathy. Although more than 280 human EV serotypes exist, only four serotypes have licenced vaccines. No antiviral drugs are available to treat EV infections, and global surveillance of EVs has not been effectively coordinated. Therefore, poliovirus still circulates, and there have been alarming epidemics of non-polio enteroviruses. Thus, there is a pressing need for coordinated preparedness efforts against EVs.This review provides a perspective on recent enterovirus outbreaks and global poliovirus eradication efforts with continuous vaccine development initiatives. It also provides insights into the challenges and opportunities in EV vaccine development. Given that traditional whole-virus vaccine technologies are not suitable for many clinically relevant EVs and considering the ongoing risk of enterovirus outbreaks and the potential for new emerging pathogenic strains, the need for new effective and adaptable enterovirus vaccines is emphasized.This review also explores the difficulties in translating promising vaccine candidates for clinical use and summarizes information from published literature and clinical trial databases focusing on existing enterovirus vaccines, ongoing clinical trials, the obstacles faced in vaccine development as well as the emergence of new vaccine technologies. Overall, this review contributes to the understanding of enterovirus vaccines, their role in public health, and their significance as a tool for future preparedness.

show abstract

Section: Enterovirusesmentioning

confidence: 99%

Enteroviruses: epidemic potential, challenges and opportunities with vaccines

Jartti,

Flodström-Tullberg,

Hankaniemi

2024

J Biomed Sci

View full text Add to dashboard Cite

show abstract

“…Among the previously studied molecules of EV inhibitors with known mechanism of action, several types can be mentioned: 1) capsid binders (for example, pleconaril, pokapavir, pirodavir, vapendavir, disoxaril), which prevent virus penetration into the cell; 2) inhibitors of viral proteases (namely, rupintrivir and AG7404); 3) inhibitors of viral polymerase (ribavirin, gemcitabine, amiloride); 4) viral ATPase inhibitors such as dibucaine and uoxetine [18][19][20][21]. Despite their encouraging activity in vitro and further preclinical and clinical studies, none of them have been approved by FDA for EVI medication due to lack of e cacy, poor pharmacokinetic properties, and/or adverse effects [18,20,22].…”

Section: Introductionmentioning

confidence: 99%

Benzocaine-N-acylindoline Conjugates: Synthesis and Antiviral Activity Against Coxsackievirus B3

Volobueva,

Shetnev,

Mikhalski

et al. 2023

Preprint

View full text Add to dashboard Cite

Indoline-5-sulfonamide derivatives of benzocaine have been synthesized using a sequence of three reactions: N-acylation, sulfochlorination, and sulfamidation, and their antienteroviral activity has been evaluated. Two compounds, namely, ethyl 4-((1-(cyclobutanecarbonyl)indoline)-5-sulfonamido)benzoate and ethyl 4-((1-benzoylindoline)-5-sulfonamido)benzoate exhibited a medium level of activity against coxsackievirus B3 (Nancy strain) in vitro. Their antiviral potential is exerted upon prophylactic application when added to cell culture before infection with the virus.

show abstract